Vaccine News and Research

Latest Vaccine News and Research

Positive results from Phase 3 trial of ipilimumab in patients with metastatic melanoma

Bristol-Myers Squibb Company today announced positive results from a Phase 3 randomized, double blind study of ipilimumab which demonstrated that overall survival was significantly extended in patients with previously-treated metastatic melanoma who received ipilimumab.

7 Jun 2010

NewLink Genetics reports positive data from Phase 2 trial of HyperAcute-Pancreas cancer immunotherapy

NewLink Genetics Corporation today announced positive Phase 2 clinical trial data of its HyperAcute®-Pancreas cancer immunotherapy combined with standard adjuvant chemotherapy in patients with surgically resectable pancreatic cancer. The study results suggest a potentially longer disease-free survival and one-year overall survival in this patient group than reported in previous studies of surgery and adjuvant therapy alone. These data were presented in a poster session at the American Society of Clinical Oncology (ASCO) annual meeting.

7 Jun 2010

Celldex reports interim positive results from rindopepimut Phase 2b study for GBM at ASCO

Celldex Therapeutics, Inc. today announced that interim results from a Phase 2b study evaluating rindopepimut (formerly PF-04948568 or CDX-110) in newly-diagnosed glioblastoma multiforme (GBM) patients were presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO).

7 Jun 2010

New clinical research findings on oncology to be highlighted at ASCO 2010

Researchers from University Hospitals Case Medical Center's Ireland Cancer Center will present new clinical research findings at the 46th Annual Meeting of The American Society of Clinical Oncology June 4-8 in Chicago.

5 Jun 2010

High IL-10 levels in tumor cells may decrease effectiveness of autologous melanoma vaccine: Study

Scientists from the Kimmel Cancer Center at Jefferson have found that interleukin-10 production in tumor cells is a possible prognostic factor in patients with advanced melanoma who are treated with autologous melanoma cell vaccine. They are presenting their data at the 2010 ASCO Annual Meeting in Chicago (Abstract #8588).

5 Jun 2010

BMJ report questions WHO advisors' ties to pharmaceutical industry

"Key scientists behind World Health Organization advice on stockpiling of pandemic flu drugs had financial ties with companies which stood to profit," according to a joint investigation by BMJ in collaboration with the Bureau of Investigative Journalism, BBC News reports (6/4).

5 Jun 2010

Preclinical data of dual TLR7 and TLR8 agonist in cancer published

Idera Pharmaceuticals, Inc. today announced the publication of data from studies of a dual agonist of Toll-like Receptor 7 and TLR8 in preclinical models of cancer. The Company created this first-in-class RNA-based dual agonist of TLR7 and TLR8 through its chemistry-based approach to identifying novel TLR-targeted drug candidates.

4 Jun 2010

Scancell's ImmunoBody vaccine technologies to be combined with ImmuneRegen's Homspera

Scancell Holdings Plc, the developer of therapeutic cancer vaccines, today announces a strategic collaboration with ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc.. Under the agreement, Scancell and ImmuneRegen will work together to investigate the synergy between ImmuneRegen's Homspera® and Scancell's ImmunoBody® vaccine technologies.

4 Jun 2010

Caltech biologists pinpoint molecular changes that help allow global spread of resistance to Tamiflu

Biologists at the California Institute of Technology have pinpointed molecular changes that helped allow the global spread of resistance to the antiviral medication Tamiflu (oseltamivir) among strains of the seasonal H1N1 flu virus.

4 Jun 2010

Merck launches Oncology Collaborative Trials Network

Today, Merck announced the launch of the Merck Oncology Collaborative Trials Network, a pioneering clinical trial network focusing on the development of Merck drug and vaccine candidates being investigated for the treatment and prevention of cancer. The global network comprises leading cancer research centers who will partner with Merck to speed the development of innovative treatments for a range of cancers.

4 Jun 2010

WHO says H1N1 remains pandemic

WHO Director-General Margaret Chan on Thursday announced the WHO still considers H1N1 (swine) flu a pandemic, despite the fact "its most intense activity has passed in many parts of the world," Reuters reports (Lynn, 6/3).

4 Jun 2010

Intellect Neurosciences receives USPTO Notice of Allowance for IN-N01 monoclonal antibody patent

Intellect Neurosciences, Inc. announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent related to the Company's humanized monoclonal antibody, IN-N01, being developed as a disease-modifying treatment for Alzheimer's disease and other related indications.

4 Jun 2010

Amorfix Life Sciences signs licensing agreement with PREVENT

Amorfix Life Sciences Ltd. and Pan-Provincial Vaccine Enterprise Inc. of Saskatoon, Saskatchewan, today announced that the two groups have entered into a licensing agreement granting PREVENT exclusive worldwide rights to Amorfix's lead amyotrophic lateral sclerosis vaccines.

3 Jun 2010

Life Technologies makes equity investment in SGI

Life Technologies Corporation, a provider of innovative life science solutions, announced today that it has made an equity investment in Synthetic Genomics, Inc., a privately held company founded to commercialize synthetic genomic advances. Terms of the investment were not disclosed.

3 Jun 2010

Novel anti-malarial drug developed from blood thinner by Australian scientists

Malaria caused by a parasite that is borne in female mosquitoes and that spreads in humans through mosquito bites is a major public health problem and it kills more than a million people world wide each year. With the rise of resistance of many of the strains of the malaria parasite to most of the anti-malarial drugs the problem is escalating at an alarming pace.

2 Jun 2010

Data on ImmunoCellular Therapeutics' ICT-107 for GBM to be presented at 46th ASCO

ImmunoCellular Therapeutics, Ltd. a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that data from a recent clinical trial of ICT-107, the company's dendritic cell based cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), will be presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 4-8 in Chicago.

2 Jun 2010

Bangalore INDIA BIO 2010 inaugurated

Bangalore INDIA BIO 2010, India's premier Biotechnology event organized by the Department of Information Technology, Biotechnology and Science & Technology, Government of Karnataka, Vision Group on Biotechnology and MM Activ Sci-Tech Communications Co was inaugurated today by Shri B.S. Yeddyurappa, Hon'ble Chief Minister of Karnataka, and Shri Katta Subramanya Naidu - Hon'ble Minister for IT & BT, Information, Excise and BWSSB, Government of Karnataka.

2 Jun 2010

Barriers, misinformation still prevent many from seeking flu protection for their families: Canadian Flu Report

According to the Canadian Flu Report released today, 40 per cent of parents are now more interested in vaccinating themselves and their children against seasonal flu following last year's H1N1 outbreak. Yet, significant barriers and misinformation are still preventing many from actually seeking proper flu protection for their families.

2 Jun 2010

Research findings advance the effort to develop AIDS vaccine

In findings that contribute to efforts to design an AIDS vaccine, a team led by Scripps Research Institute scientists has determined the structure of an immune system antibody molecule that effectively acts against most strains of human immunodeficiency virus, the virus that causes AIDS.

2 Jun 2010

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.

2 Jun 2010

Vaccine News and Research

Latest Vaccine News and Research

Positive results from Phase 3 trial of ipilimumab in patients with metastatic melanoma

NewLink Genetics reports positive data from Phase 2 trial of HyperAcute-Pancreas cancer immunotherapy

Celldex reports interim positive results from rindopepimut Phase 2b study for GBM at ASCO

New clinical research findings on oncology to be highlighted at ASCO 2010

High IL-10 levels in tumor cells may decrease effectiveness of autologous melanoma vaccine: Study

BMJ report questions WHO advisors' ties to pharmaceutical industry

Preclinical data of dual TLR7 and TLR8 agonist in cancer published

Scancell's ImmunoBody vaccine technologies to be combined with ImmuneRegen's Homspera

Caltech biologists pinpoint molecular changes that help allow global spread of resistance to Tamiflu

Merck launches Oncology Collaborative Trials Network

WHO says H1N1 remains pandemic

Intellect Neurosciences receives USPTO Notice of Allowance for IN-N01 monoclonal antibody patent

Amorfix Life Sciences signs licensing agreement with PREVENT

Life Technologies makes equity investment in SGI

Novel anti-malarial drug developed from blood thinner by Australian scientists

Data on ImmunoCellular Therapeutics' ICT-107 for GBM to be presented at 46th ASCO

Bangalore INDIA BIO 2010 inaugurated

Barriers, misinformation still prevent many from seeking flu protection for their families: Canadian Flu Report

Research findings advance the effort to develop AIDS vaccine

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in